Christian Buske, MD from the University Hospital Ulm, Ulm, Germany discusses his highlights from the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. Chemotherapy-free approaches are becoming more dominant in the field and appear to be effective in several indolent B-cell lymphomas. For chronic lymphocytic leukemia (CLL), impressive results have been shown by using chemotherapy for debulking, and treating the patient with a combination of the BCL-2 inhibitor ABT-199 (venetoclax) and the second-generation anti-CD20 antibody, obinutuzumab. In follicular lymphoma, the PI3K inhibitor copanlisib, as a single agent, is able to induce response rates of approximately 60% in relapsed/refractory patients. In diffuse large B-cell lymphoma (DLBCL), chemotherapy is a backbone of treatment but Prof. Buske points out new developments with the new antibody MOR208 targeting CD19 that shows promise in combination with lenalidomide. This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.